RPS11B Antibody

What is RPS11 and why is it of interest in molecular research?

RPS11 is a member of the S17P family of ribosomal proteins and serves as a crucial component of the 40S ribosomal subunit. It plays an essential role in protein synthesis by facilitating ribosome assembly and translation processes. RPS11 has gained significant research interest due to its dysregulation in various pathological conditions, particularly cancer and genetic disorders . Recent studies have demonstrated that elevated RPS11 levels are associated with poor prognosis in hepatocellular carcinoma (HCC), making it a potential biomarker for tumor progression and recurrence .

What applications are RPS11 antibodies validated for in research settings?

RPS11 antibodies have been validated for multiple research applications including Western blot (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA). For instance, the RPS11 Antibody (PACO29188) has been specifically validated with recommended dilutions of 1:1000-1:5000 for WB, 1:20-1:200 for IHC, and 1:2000-1:10000 for ELISA applications . When selecting an antibody for research, it's critical to verify that it has been validated for your specific application and target species to ensure reliable results.

What is the molecular characterization of the RPS11 protein that antibodies target?

RPS11 has a molecular weight of approximately 18.4 kDa and is encoded by a gene located on chromosome 19q13.3 in humans. The protein functions primarily as a structural component of ribosomes but also participates in mRNA catabolic processes, rRNA processing, and translational initiation . RPS11 antibodies are typically designed to target specific epitopes within the protein sequence (amino acids 2-158), allowing for precise detection across various experimental contexts . Understanding this molecular profile is essential for proper antibody selection and experimental design.

How should researchers optimize IHC protocols when using RPS11 antibodies for cancer tissue analysis?

When utilizing RPS11 antibodies for IHC in cancer tissue analysis, researchers should employ a standardized protocol that includes proper antigen retrieval methods. Based on published methodologies, researchers have successfully used RPS11 antibodies (such as Abcam, Cat No# ab175213) at a dilution of 1:100 with overnight incubation at 4°C . Antigen retrieval can be performed using citrate buffer pH 6.0 followed by blocking with hydrogen peroxide solution. For visualization, diaminobenzidine (DAB) solution works effectively with RPS11 antibodies, while Harris' Hematoxylin provides appropriate nuclear counterstaining .

To quantify RPS11 expression, the H-score method has proven valuable, multiplying staining intensity (0-3) by staining extent (0-100%). This approach allows categorization of samples into negative (0), weak (0-100%), moderate (100-150%), and strong (150-300%) expression groups for statistical analysis and clinicopathological correlation . These methodological details are critical for reproducible research and valid cross-study comparisons.

What strategies can address cross-reactivity concerns when working with RPS11 antibodies?

Cross-reactivity is a significant concern when working with antibodies against ribosomal proteins like RPS11, which share structural similarities with other ribosomal components. To address this challenge, researchers should implement multiple validation approaches. First, verify antibody specificity through Western blot analysis, confirming a single band at the expected 18 kDa size as demonstrated with the PACO29188 antibody . Second, include proper negative controls (samples where the primary antibody is omitted) and positive controls (tissues or cell lines known to express RPS11).

For particularly sensitive experiments, consider validating antibody specificity using RPS11 knockdown/knockout cells or through peptide competition assays. Additionally, pre-absorption of the antibody with recombinant RPS11 protein can help identify non-specific binding. When studying RPS11 in complex samples, parallel detection with multiple antibodies targeting different epitopes of RPS11 provides further confidence in specificity.

How should researchers interpret contradictory RPS11 expression data between different detection methods?

When facing discrepancies in RPS11 expression data between methodologies (e.g., IHC showing high expression while Western blot indicates modest levels), researchers should systematically investigate potential causes rather than simply discarding data. First, evaluate technical factors: antibody sensitivity varies between applications—some antibodies perform better in native conditions (IHC) versus denatured states (Western blot) .

Second, consider sample preparation differences; protein extraction methods might affect RPS11 detection efficiency, particularly if the protein is tightly associated with cellular structures. Third, explore biological explanations such as post-translational modifications or splice variants that might be differentially detected by various antibodies or methods. Finally, quantification approaches differ fundamentally between techniques—IHC H-scoring systems measure both intensity and extent of staining , while Western blot quantification typically normalizes to loading controls.

To resolve such contradictions, researchers should triangulate findings using orthogonal methods such as qRT-PCR to measure RPS11 mRNA levels, which has successfully demonstrated differential expression between cancer and normal cell lines . When publishing, transparently report all contradictory findings and proposed explanations rather than selectively presenting data that supports a particular hypothesis.

What controls and validation steps are essential when using RPS11 antibodies in hepatocellular carcinoma research?

In hepatocellular carcinoma research using RPS11 antibodies, researchers must implement comprehensive controls and validation steps to ensure reliable outcomes. For IHC experiments, include normal liver tissue adjacent to tumors as internal controls, which typically shows lower RPS11 expression compared to tumor tissue . Additionally, incorporate established HCC cell lines with known RPS11 expression profiles (e.g., MHCC97H, MHCCLM3) as positive controls, and non-transformed hepatic cell lines (L02) as negative or baseline controls .

For validation, researchers should confirm antibody specificity through Western blot analysis, verifying a single band at the expected 18 kDa molecular weight. Further validation through qRT-PCR to correlate protein expression with mRNA levels strengthens confidence in antibody performance . When developing prognostic models incorporating RPS11 expression, validation in independent patient cohorts is essential, as demonstrated in previous studies utilizing training (n=182) and validation (n=90) cohorts . This multi-level validation approach ensures that findings based on RPS11 antibody staining are reproducible and biologically relevant.

What methodological approaches allow for quantitative analysis of RPS11 expression in tissue microarrays?

For quantitative analysis of RPS11 expression in tissue microarrays (TMAs), researchers should employ standardized scoring systems coupled with digital image analysis. The H-score method has been successfully applied in RPS11 research, multiplicatively combining staining intensity scores (negative: 0, weak: 1, moderate: 2, strong: 3) with the percentage of stained cells (0-100%) . This produces a comprehensive score ranging from 0-300 that enables statistical comparison across samples.

To minimize subjectivity, assessment should be conducted independently by two pathologists blinded to clinical data, with discrepancies resolved through consensus review . For larger studies, consider employing digital pathology platforms with machine learning algorithms to analyze RPS11 staining patterns consistently across numerous samples. These platforms can be trained to recognize staining intensity and cellular localization patterns, providing continuous data rather than categorical assessments.

After scoring, stratification of samples into expression groups (negative, weak, moderate, strong) facilitates correlation with clinicopathological features and survival outcomes . Statistical validation of cutoff values through methods like receiver operating characteristic (ROC) curve analysis ensures optimal discrimination between prognostic groups. This methodological rigor enhances reproducibility and translational relevance of RPS11 antibody-based research.

How can researchers differentiate between specific and non-specific binding when using RPS11 antibodies in complex tissue samples?

Differentiating specific from non-specific binding with RPS11 antibodies in complex tissues requires multiple technical approaches. First, implement a titration series to determine optimal antibody concentration—excessive antibody leads to background staining while insufficient antibody reduces true signal detection. Based on published protocols, a 1:100 dilution has been effective for IHC applications with commercial RPS11 antibodies , while Western blot applications typically use 1:1000-1:5000 dilutions .

Second, include absorption controls where the primary antibody is pre-incubated with recombinant RPS11 protein before tissue application; specific staining should disappear while non-specific staining persists. Third, compare staining patterns across multiple antibodies targeting different RPS11 epitopes—consistent patterns suggest specific binding while discrepancies warrant further investigation.

Fourth, validate subcellular localization patterns against known RPS11 distribution in cellular compartments (cytoplasm, cytosol, focal adhesion, membrane, nucleolus, nucleoplasm) . Finally, correlate protein detection with mRNA expression data from parallel tissue sections to confirm biological relevance of observed staining. These comprehensive measures collectively enhance confidence in distinguishing authentic RPS11 signals from artifacts.

How should researchers analyze correlations between RPS11 expression and clinicopathological features in cancer studies?

When analyzing correlations between RPS11 expression and clinicopathological features in cancer, researchers should employ a systematic statistical approach. First, categorize samples into distinct expression groups based on standardized scoring methods; previous research successfully divided samples into high versus low RPS11 expression groups using the H-score method . Then, analyze associations using appropriate statistical tests—chi-square or Fisher's exact test for categorical variables and t-test or Mann-Whitney test for continuous variables.

Published studies have demonstrated significant associations between high RPS11 expression and elevated AFP levels (P=0.021), CA19-9 levels (P=0.002), ALP levels (P=0.003), and poor tumor differentiation (P=0.022) in HCC patients . These findings were consistent across independent validation cohorts, strengthening their reliability. Beyond simple associations, researchers should explore multivariate analyses to identify independent prognostic factors and develop integrated prognostic nomograms incorporating RPS11 expression alongside other significant clinical variables .

When reporting results, present comprehensive data tables showing the distribution of all clinicopathological features stratified by RPS11 expression levels, including appropriate statistical values and significance thresholds, similar to the methodical presentation in HCC studies . This thorough approach enables meaningful interpretation of RPS11's biological significance in disease pathogenesis.

What experimental design best elucidates the mechanistic role of RPS11 in cancer progression?

Elucidating RPS11's mechanistic role in cancer progression requires a multifaceted experimental approach beyond simple expression analysis. An optimal design combines in vitro functional studies with in vivo models and clinical sample analysis. Begin with manipulation of RPS11 expression in relevant cell lines using overexpression and knockdown/knockout strategies via plasmid transfection or CRISPR-Cas9 techniques. Phenotypic assays (proliferation, migration, invasion, apoptosis) following RPS11 modulation reveal its functional impact on cancer hallmarks.

To explore molecular mechanisms, perform RNA-sequencing and proteomics analysis on RPS11-modulated cells to identify dysregulated pathways. Co-immunoprecipitation experiments using validated RPS11 antibodies can identify protein-protein interactions beyond its canonical ribosomal function. In parallel, develop xenograft models with RPS11-modulated cancer cells to assess in vivo growth characteristics and metastatic potential.

Validate findings in primary human samples by correlating RPS11 expression with documented pathway markers in tissue microarrays. The integration of these approaches has successfully established connections between ribosomal proteins and cancer progression, as demonstrated in HCC studies showing that high RPS11 levels correlate with poor survival and increased recurrence . This comprehensive experimental framework provides mechanistic insights rather than merely descriptive associations.

What strategies effectively address variability in RPS11 antibody performance across different experimental batches?

Addressing batch-to-batch variability in RPS11 antibody performance requires implementation of robust quality control procedures. First, maintain detailed records of antibody lot numbers and performance characteristics. When receiving new antibody lots, perform side-by-side validation with previously validated lots using positive control samples (e.g., cell lines with confirmed RPS11 expression). This comparative approach allows detection of sensitivity or specificity differences.

Second, implement standardized protein loading controls and consistent sample preparation protocols across experiments. For Western blot applications, always include recombinant RPS11 protein standards at known concentrations to generate standard curves for quantitative comparisons between batches . For IHC applications, incorporate tissue microarrays containing reference samples spanning negative to strong RPS11 expression as internal controls in each staining run .

Third, normalize results using multiple housekeeping proteins or reference tissues rather than relying on single references. Finally, consider preparing large batches of working antibody dilutions that can be aliquoted and stored according to manufacturer recommendations (typically at -20°C with 50% glycerol) to minimize freeze-thaw cycles and maintain consistent antibody performance across experiments.

How can researchers optimize Western blot protocols specifically for RPS11 detection?

Optimizing Western blot protocols for RPS11 detection requires attention to several critical parameters. First, select appropriate protein extraction methods—RIPA buffer with protease inhibitors effectively isolates RPS11 while preserving its integrity. Given RPS11's relatively low molecular weight (18 kDa) , use higher percentage (15%) polyacrylamide gels for optimal resolution in the lower molecular weight range, with extended running times to ensure proper band separation from other small proteins.

Second, during transfer, use PVDF membranes with 0.2 μm pore size rather than standard 0.45 μm to prevent potential protein pass-through. Optimize transfer conditions with 20% methanol and lower current (150-200 mA) for 1-2 hours to ensure efficient transfer of small proteins. For blocking, 5% non-fat dry milk in TBST has proven effective in preventing non-specific binding with RPS11 antibodies.

Third, incubate with primary RPS11 antibody at recommended dilutions (1:1000-1:5000) overnight at 4°C to maximize specific binding. For detection, HRP-conjugated secondary antibodies at 1:10,000 dilution provide optimal signal-to-noise ratio . When developing, use enhanced chemiluminescence with shorter exposure times initially (30 seconds) to avoid signal saturation. This methodological refinement ensures consistent and specific RPS11 detection across experimental conditions.